Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;9(11):103931.
doi: 10.1016/j.esmoop.2024.103931. Epub 2024 Oct 11.

Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar

M Fakih  1 , G W Prager  2 , J Tabernero  3 , N Amellal  4 , E Calleja  5 , J Taieb  6
Affiliations
Review

Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar

M Fakih et al. ESMO Open. 2024 Nov.

Abstract

Currently, there is no consensus definition for clinically meaningful outcomes in randomized clinical trials (RCTs) designed to evaluate new treatments for patients with refractory metastatic colorectal cancer (mCRC). Since 2014, recommended targets for improvements in overall survival and progression-free survival have been published by several societies, including those from the American Society of Clinical Oncology (ASCO) Clinically Meaningful Outcomes Working Group in 2014, the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) in 2015, and Colorectal Cancer Canada (CCC) consensus statements in 2019. However, evidence from several systematic reviews suggests that in a substantial proportion of RCTs that led to oncology drug approvals, the recommended thresholds of ASCO and ESMO-MCBS were not met. In addition to efficacy and safety, quality of life (QoL) is important to patients with mCRC, especially for those who are receiving later-line therapy or end-of-life care. As such, both ESMO-MCBS and CCC recommend the inclusion of QoL assessments in the design of mCRC clinical trials. Since the publication of the ASCO recommendations in 2014, there has been significant progress in the development of treatment options for patients with refractory mCRC; these include the approvals of trifluridine/tipiracil (FTD/TPI) as a single agent and in combination with bevacizumab, and the approval of fruquintinib. Among the phase III RCTs in third-line mCRC, only the SUNLIGHT trial of FTD/TPI plus bevacizumab met all recommended thresholds for clinically meaningful improvements, while also demonstrating a manageable safety profile and slower deterioration in multiple measures of QoL compared with FTD/TPI alone. The results from the SUNLIGHT study show that incremental gains in several clinically meaningful endpoints are achievable, thus raising the bar in defining clinically meaningful outcomes for emerging therapies in refractory mCRC.

Keywords: clinically meaningful; colorectal cancer; metastatic; quality of life; survival.

PubMed Disclaimer

References

    1. Ko Y.J., Abdelsalam M., Kavan P., et al. What is a clinically meaningful survival benefit in refractory metastatic colorectal cancer? Curr Oncol. 2019;26:255–259. - PMC - PubMed
    1. Cherny N.I., Dafni U., Bogaerts J., et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28:2340–2366. - PubMed
    1. Ellis L.M., Bernstein D.S., Voest E.E., et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277–1280. - PubMed
    1. Schnog J.B., Samson M.J., Gans R.O.B., Duits A.J. An urgent call to raise the bar in oncology. Br J Cancer. 2021;125:1477–1485. - PMC - PubMed
    1. Moon D.H., Chen R.C. Defining a clinically meaningful benefit in cancer clinical trials: from the perspectives of the clinical trialist, patient, and society. JNCI Cancer Spectr. 2018;2 - PMC - PubMed

MeSH terms